Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RiLEY: Elraglusib + Retifanlimab + Gem/Abraxane in Pancreatic Cancer
NCT05239182Phase 2Terminated
- Start
- Jan 2022
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of elraglusib in pancreatic adenocarcinoma (PDAC). Started Jan 2022; status: terminated.
02
Drugs
elraglusib
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT05239182.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05239182.